Navigation Links
Metamark and HistoRx Announce Licensing Agreement for AQUA® Technology
Date:12/20/2010

CAMBRIDGE, Mass. and BRANFORD, Conn., Dec. 20, 2010 /PRNewswire/ -- Metamark Genetics, Inc., a privately held oncology-focused molecular diagnostics company, and HistoRx, Inc., a diagnostics company developing tissue-based diagnostic solutions to advance individualized patient care, today announced a multi-year licensing agreement.  HistoRx has granted Metamark a worldwide license to the AQUA technology for the clinical commercialization of Metamark's proprietary MetamarkDx™ Prognostic Assays.  

For several years, Metamark has engaged HistoRx for research work in support of Metamark diagnostic assays based on HistoRx's proprietary AQUA technology.   The two companies have been working to achieve key validation milestones prior to finalizing this agreement.  Metamark's proprietary MetamarkDx Prognostic Assays will evaluate the molecular profile of an individual patient's tumor through quantitative expression analysis of Metamark's proprietary Prognosis Determinants™. This will enable the identification of those early stage cancers that are genetically hardwired for lethal spread, as well as those that are less aggressive, thus arming physicians with critical insight to be able to guide their patients towards more personalized treatment strategies.

The licensed portfolio includes assays performed using HistoRx's proprietary technology for analysis of fluorescent immunohistochemistry, enabling quantitative assessment of specific biomarkers for patients with certain solid tumors.  

"We are delighted to be working with HistoRx and are eager to develop and validate clinical diagnostics for key biomarkers using AQUA technology, and to ultimately commercialize them for the benefit of patients around the world," said Mark Straley, President and Chief Executive Officer of Metamark.  "Metamark's powerful Prognosis Determinants™ technology, and the multimarker assay panels developed from it, requires objective and reproducible quantitative measurement of protein biomarkers – something specifically enabled by HistoRx's AQUA technology."

"Metamark's unique approach to investigating the drivers of cancer development and metastasis has tremendous potential for changing the face of these diseases," said Rana K. Gupta, CEO of HistoRx.  "We are pleased to see the ways that AQUA® technology and the collaboration between HistoRx scientists and the Metamark team have led to significant progress towards this goal."

About Metamark Genetics, Inc.

Metamark is a privately held oncology company focused on the development of function-based prognostic assays for early staged cancers. The MetamarkDx Prognostic Assays under development are based on Metamark's proprietary Prognosis Determinants, genes discovered through leading edge cancer research and demonstrated to play a causal role in promoting tumor progression and spread. For further information, please visit the company's website at www.metamarkgenetics.com.

About HistoRx, Inc.

HistoRx, Inc. is a leading developer of tissue-based diagnostic solutions to advance individualized patient care. The company's products and services are based on proprietary analysis of tissue biomarkers using AQUA technology. AQUA technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide drug development and therapeutic decision-making. HistoRx is commercializing a pipeline of proprietary diagnostic products targeting improved treatment decision-making and patient outcomes in cancer care. For more information, please visit www.historx.com.


'/>"/>
SOURCE HistoRx, Inc.; Metamark Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Metamark Genetics, Inc. Announces New Chief Executive Officer
2. Metamark Genetics, Inc. Announces New Chief Scientific Officer
3. Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors
4. Heiner Dreismann, Ph.D., Former President of Roche Molecular Systems, Joins the HistoRx Board of Directors
5. HistoRx Receives Key Patent on Application of AQUA(R) Technology to Personalized Medicine
6. Genoptix and HistoRx Announce Licensing Agreement for AQUA(R) Technology
7. HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research
8. InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe
9. Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
10. Talecris Biotherapeutics Announces Jury Verdict in Contract Dispute
11. China Cord Blood Corporation Announces Completion of Warrant Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... BETHESDA, Md. , Jan. 18, 2017  Northwest ... company developing DCVax® personalized immune therapies for operable and ... Marnix Bosch , Chief Technical Officer of NW Bio, ... Thursday, January 19, 2017, at the Hyatt Regency Hotel ... Dr. Bosch will chair the session entitled "New Therapeutic ...
(Date:1/19/2017)... LAKES, N.J. , Jan. 18, 2017 BD (Becton, ... technology company, announced today that it will host a live webcast ... at 1 p.m. (ET). The webcast can be ... be available for replay through Tuesday, January 31, 2017. ... About BD BD ...
(Date:1/18/2017)... According to a new market research report "In situ Hybridization Market by ... (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global Forecast to 2021" published ... from USD 557.1 Million in 2016, growing at a CAGR of 5.8%. ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017 ... applying mechanistic modeling to drug research and development, ... PhD, Co-Founder, President, and CEO of Applied BioMath, ... for Informatics and Modeling (BAGIM) Meeting on Thursday ... Cambridge , MA.   Dr. Burke,s ...
Breaking Biology Technology:
(Date:1/6/2017)... Jan. 5, 2017  Delta ID Inc., a leader ... technology for automotive at CES® 2017. Delta ID has ... to demonstrate the use of iris scanning as a ... the driver in a car, and as a way ... experience. Delta ID and Gentex will demonstrate ...
(Date:12/22/2016)... MOUNTAIN VIEW, Calif. , Dec. 20, 2016  As ... all levels, 23andMe, the leading personal genetics company, recently released ... Only Me . The book focuses on the topics ... the Next Generation Science Standards (NGSS) taught in elementary school ... the second in a series by illustrator Ariana Killoran ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic ... permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se ... tumor en 2017, con múltiples sitios previstos a lo largo de ... ... el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se ...
Breaking Biology News(10 mins):